You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Daratumumab

Showing 226 - 250 of 273
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma Trial in Australia, United Kingdom, United States (RO6870810, daratumumab)

Completed
  • Multiple Myeloma
  • Duarte, California
  • +11 more
Feb 6, 2020

Infusion Reaction, Monoclonal Antibody Trial in Clovis (Montelukast 10 Mg Oral Tablet)

Recruiting
  • Infusion Reaction
  • Monoclonal Antibody
  • Montelukast 10 Mg Oral Tablet
  • Clovis, California
    Community Cancer Institute
Nov 8, 2021

Multiple Myeloma Trial in Japan (JNJ-54767414 (Daratumumab), Bortezomib, Dexamethasone)

Completed
  • Multiple Myeloma
  • JNJ-54767414 (Daratumumab)
  • +2 more
  • Hiroshima, Japan
  • +4 more
Mar 5, 2019

Multiple Myeloma Trial (Melphalan and Treosulfan, Melphalan)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Dec 5, 2022

Relapsed and/or Refractory Multiple Myeloma, Relapsed and/or Refractory Non Hodgkin Lymphoma Trial in United States (MT-0169)

Recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • Relapsed and/or Refractory Non Hodgkin Lymphoma
  • Los Angeles, California
  • +6 more
Feb 28, 2022

Multiple Myeloma Stage I Trial in Salvador (Cyclo Thal Dex Daratumumab)

Unknown status
  • Multiple Myeloma Stage I
  • Cyclo Thal Dex Daratumumab
  • Salvador, Bahia, Brazil
    CEHON - Centro de Hematologia e Oncologia da Bahia
Jan 2, 2019

AL Amyloidosis Trial in France (Isatuximab)

Recruiting
  • AL Amyloidosis
  • Amiens, France
  • +14 more
Aug 9, 2022

Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)

Recruiting
  • Plasma Cell Myeloma
  • Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 27, 2022

Evan Syndrome, Treatment Trial in Tianjin (Anti-CD38 antibody Injection)

Recruiting
  • Evan Syndrome
  • Treatment
  • Anti-CD38 antibody Injection
  • Tianjin, Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
Aug 25, 2023

Multiple Myeloma Trial in Warszawa, Poznan (Daratumumab 20 MG/ML [Darzalex])

Recruiting
  • Multiple Myeloma
  • Daratumumab 20 MG/ML [Darzalex]
  • Warszawa, Mazowieckie, Poland
  • +1 more
Jan 2, 2019

Light Chain (AL) Amyloidosis Trial in Worldwide (Birtamimab, Placebo, Standard of Care Chemotherapy)

Recruiting
  • Light Chain (AL) Amyloidosis
  • Hartford, Connecticut
  • +120 more
Aug 8, 2022

Newly Diagnosed Multiple Myeloma Trial in Spain (Bortezomib, Isatuximab, Iberdomide)

Not yet recruiting
  • Newly Diagnosed Multiple Myeloma
  • Alcalá de Henares, Madrid, Spain
  • +67 more
Sep 23, 2022

Immune Thrombocytopenia, Treatment Trial in Tianjin (CM313 Injection)

Not yet recruiting
  • Immune Thrombocytopenia
  • Treatment
  • CM313 Injection
  • Tianjin, Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
Jan 12, 2023

Multiple Myeloma Trial in Athens (Daratumumab, Ixazomib, Dexamethasone)

Unknown status
  • Multiple Myeloma
  • Daratumumab, Ixazomib, Dexamethasone
  • Athens, Attica, Greece
    General Hospital of Athens "Alexandra"
Nov 20, 2018

Antibody-mediated Rejection Trial in Vienna, Berlin (Felzartamab, Placebo)

Recruiting
  • Antibody-mediated Rejection
  • Vienna, Austria
  • +1 more
Aug 23, 2022

Relapsed/Refractory Multiple Myeloma Trial in France, United States (ISB 1342)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • ISB 1342
  • Little Rock, Arkansas
  • +21 more
May 10, 2022

Antiphospholipid Syndrome, Thrombocytopenia Trial in Tianjin (Anti-CD38 antibody Injection)

Recruiting
  • Antiphospholipid Syndrome
  • Thrombocytopenia
  • Anti-CD38 antibody Injection
  • Tianjin, Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
Aug 9, 2023

Refractory Plasma Cell Myeloma Trial in Jacksonville (Dexamethasone, Elotuzumab, Pomalidomide)

Suspended
  • Refractory Plasma Cell Myeloma
  • Jacksonville, Florida
    Mayo Clinic in Florida
Oct 18, 2021

Plasma Cell Myeloma Trial in Czechia, France, United States (Isatuximab)

Completed
  • Plasma Cell Myeloma
  • Scottsdale, Arizona
  • +17 more
Apr 22, 2022

AL Amyloidosis, Plasma Cell Dyscrasia Trial in Nanjing

Enrolling by invitation
  • AL Amyloidosis
  • Plasma Cell Dyscrasia
    • Nanjing, Jiangsu, China
      National Clinical Research Center of Kidney Diseases, Jinling Ho
    Jan 26, 2021

    Plasma Cell Leukemia Trial in United States (Bortezomib, Daratumumab, Dexamethasone)

    Withdrawn
    • Plasma Cell Leukemia
    • Duarte, California
    • +4 more
    Dec 17, 2018

    Relapsed, Refractory Multiple Myeloma Trial in Milwaukee (RAPA-201 Autologous T cells)

    Recruiting
    • Relapsed, Refractory Multiple Myeloma
    • RAPA-201 Autologous T cells
    • Milwaukee, Wisconsin
      Medical College of Wisconsin
    Dec 28, 2021

    Multiple Myeloma Trial (Belantamab mafodotin (GSK2857916) anti-BCMA-immunoconjugate)

    Approved for marketing
    • Multiple Myeloma
    • Belantamab mafodotin (GSK2857916) anti-BCMA-immunoconjugate
    • (no location specified)
    Mar 9, 2021

    Malignant Tumors Stated as Primary Lymphoid Haematopoietic Trial (Daratumumab)

    Withdrawn
    • Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
    • Daratumumab
    • (no location specified)
    Jul 23, 2018

    Multiple Myeloma Trial in Netherlands (Iberdomide plus low-dose cyclophosphamide and dexamethasone)

    Recruiting
    • Multiple Myeloma
    • Iberdomide plus low-dose cyclophosphamide and dexamethasone
    • Alkmaar, Netherlands
    • +8 more
    Oct 5, 2021